IGF1R and colorectal carcinoma: An in vitro study has shown that the regimen of anti-EGFR mAb ICR62 plus IGF1R tyrosine kinase inhibitor NVP-AEW541 can synergistically enhance the antitumor effect in some CRC cells [145].